Ghosh S, Rao A K
Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140.
Thromb Res. 1993 Jun 1;70(5):417-22. doi: 10.1016/0049-3848(93)90083-z.
Administration of 1-desamino-8-D-arginine vasopressin (DDAVP), a synthetic vasopressin derivative, causes an increase in plasma factor VIII and von Willebrand factor (vWF). Recently, evidence has become available that intravenous infusion of DDAVP shortens the prolonged bleeding times in some patients with primary platelet defects even though their plasma levels of vWF and FVIII are normal prior to drug administration. The mechanism of this effect of DDAVP has not been well defined and it has been generally considered that the beneficial effect on the bleeding time is related to the rise in plasma vWF and its impact on platelet adhesion to subendothelial components including collagen, an important step in hemostasis. Thus, studies aimed at understanding the effect of DDAVP have focused on vWF-mediated adhesion of platelets to the subendothelium. For example, Sakariassen et al studied the platelet adherence to human arterial subendothelium and concluded that DDAVP improves hemostasis by causing enhanced vWF-mediated platelet adherence. This mechanism would explain the shortening of the bleeding time in patients with milder forms of vWD with subnormal levels of vWF. But patients with congenital platelets defects have normal plasma vWF raising the possibility that there may be other mechanisms contributing to the beneficial effect of DDAVP. It is clear that platelets can interact directly with collagen, mediated by specific platelet binding sites. Further, DDAVP binds to platelets even though by itself does not activate them. The present investigation was designed to elucidate whether DDAVP had any effect on the direct adhesion of platelets to collagen in the absence of mediation by vWF. Hashemi et al have suggested that the effect of DDAVP on endothelial cell release of vWF is mediated by an as yet uncharacterized intermediate factor(s) released from peripheral mononuclear cells. Therefore, we studied the effect also of plasma samples obtained from patients treated with DDAVP on adhesion of platelets to collagen.
给予1-去氨基-8-D-精氨酸加压素(DDAVP),一种合成的加压素衍生物,会导致血浆因子VIII和血管性血友病因子(vWF)增加。最近,有证据表明,静脉输注DDAVP可缩短一些原发性血小板缺陷患者延长的出血时间,尽管在给药前他们的血浆vWF和FVIII水平正常。DDAVP这种作用的机制尚未明确,一般认为其对出血时间的有益作用与血浆vWF的升高及其对血小板黏附于包括胶原蛋白在内的内皮下成分的影响有关,这是止血过程中的重要一步。因此,旨在了解DDAVP作用的研究集中在vWF介导的血小板与内皮下的黏附。例如,Sakariassen等人研究了血小板与人动脉内皮下的黏附,并得出结论,DDAVP通过增强vWF介导的血小板黏附来改善止血。这种机制可以解释vWF水平低于正常的较轻形式vWD患者出血时间的缩短。但先天性血小板缺陷患者的血浆vWF正常,这增加了可能存在其他机制导致DDAVP产生有益作用的可能性。很明显,血小板可以通过特定的血小板结合位点直接与胶原蛋白相互作用。此外,DDAVP可与血小板结合,尽管其本身不会激活血小板。本研究旨在阐明在没有vWF介导的情况下,DDAVP是否对血小板与胶原蛋白的直接黏附有任何影响。Hashemi等人提出,DDAVP对内皮细胞释放vWF的作用是由外周单核细胞释放的一种尚未明确的中间因子介导的。因此,我们还研究了从接受DDAVP治疗的患者获得的血浆样本对血小板与胶原蛋白黏附的影响。